Haematologica 2004;89: supplement no. 8 - Supplements ...

More documents

Recommendations

Info

XVIII Congress of the Italian Society for Hemostasis and Thrombosis Research, Rome, Sept. 30-Oct. 3, 20041173) pyruvate+NADH (arrow) lactate+NADThe chromatographic procedure included reductionof disulfide bonds by NaBH4, use of cysteamineas internal standard, derivatization with ammonium-7-fluorobenzo-2-oxa-diazole-4-sulphonate(SBD-F), and fluorescence detection after separationby reversed-phase HPLC. Medians and ranges of tHcyplasma levels (n=96) observed were: 16.1 (3.9-61.8)and 17.5 (4.9-58.3) µmol/L for HPLC and enzymickit, respectively. Linear regression analysis yielded:enzymic assay = 1.044 (± 0.546) + 1.011(± 0.024)HPLC (±SE), r = 0.975, Sx/y = 2.85 (p
118Postersrelated to an acute inflammatory response. Thesenoninvasive indexes may help in further examiningT1DM pathophysiology and monitoring pharmacologicalinterventions to interfere with disease developmentand progression.PO-048THE ROLE OF CRP IN THE OUTCOME OF CARDIOVASCULAREVENTS IN TYPE-2 DIABETIC PATIENTS: THE GENDIABE STUDYZito F,* Di Castelnuovo A,* Ciccarone E,* #Capani F, # Volpi R, § Donati MB,* Iacoviello L,*on behalf of the GENDIABE Investigators*Laboratory of Genetic and EnvironmentalEpidemiology, Center for High Technology Researchand Education in Biomedical Sciences, CatholicUniversity of Campobasso, Italy; # Department ofMedicine and Aging, University of Chieti, Italy;§3 rd Laboratory, Spedali di Brescia, ItalyBackground. CRP is an acute phase protein producedby the liver in response to inflammatory stimulileading to high IL6 levels. CRP is high in subjectswith cardiovascular disease (CVD) and predicts therisk of cardiovascular events in both stable andunstable angina. It is also found high in subjects withtype-2 diabetes. CRP levels are influenced by severalfactors such as gender, obesity, socio-economicclass, alcohol. A recently developed high-sensitivitymethod to detect CRP (hsCRP) is presently the mostlargely used in CVD assessment. Aim and Methods.We aimed at investigating the association of hsCRPlevels with macrovascular events (AMI, stroke andunstable angina) in the GENDIABE population oftype-2 diabetics. GENDIABE is a case-control studyconducted in Central Italy (Diabetology Unit ofPescara) between 1997 and 2000. 837 diabeticpatients were consecutively included into the study:301 were cases (with CVD events) and 536 controls(without CVD). We measured hsCRP (immunoturbidimetricassay) with other biochemical markers such asblood glucose, total cholesterol, tryglycerides, glycosilatedhaemoglobin (HbA1). We also consideredthe duration of diabetes as a prognostic indicator.Results. Cases were 301 (36%) and controls were536 (64%), as expected by the prevalence of CVD intype-2 diabetes. Higher hsCRP (p=0.03), male gender(p=0.001), higher age (p=0.0006), longer duration ofdiabetes (p
Page 5 and 6:
haematologicaThe origin and power o
Page 7 and 8:
XVIII Congress of the Italian Socie
Page 9 and 10:
XVIII Congress of the Italian Socie
Page 11 and 12:
2Educational Sessionssurgery. In av
Page 13 and 14:
4Educational Sessionsclinical relev
Page 15 and 16:
6Educational SessionsTREATMENT OF S
Page 17 and 18:
8Educational Sessionssioners, aceno
Page 19 and 20:
10Educational Sessionshaematologica
Page 21 and 22:
12Selected Oral Communicationsleste
Page 23 and 24:
14Selected Oral Communications11-84
Page 25 and 26:
16Selected Oral Communicationssis,
Page 27 and 28:
18Selected Oral CommunicationsSISET
Page 29 and 30:
20Oral CommunicationsCO-002LYSOSOMA
Page 31 and 32:
22Oral CommunicationsCO-006EXPRESSI
Page 33 and 34:
24Oral Communicationsshowed that th
Page 35 and 36:
26Oral CommunicationsCO-014ENOS GEN
Page 37 and 38:
28Oral Communicationsstudy demonstr
Page 39 and 40:
30Oral Communicationsmonths (2-39)
Page 41 and 42:
32Oral Communicationscompared to he
Page 43:
34Oral Communicationsoil) 2) a diet
Page 47 and 48:
38Oral CommunicationsCO-038PRACTICE
Page 49 and 50:
40Oral Communicationsjects; (ii) su
Page 51 and 52:
42Oral Communicationsindependent ri
Page 53 and 54:
44Oral Communicationsleast
Page 55 and 56:
46Oral CommunicationsCO-051DESMOPRE
Page 57 and 58:
48Oral Communicationssuring the pKa
Page 59 and 60:
50Oral Communicationsthe Table, as%
Page 61 and 62:
52Oral Communicationsels increased
Page 63 and 64:
54Oral CommunicationsCO-066NITROPRA
Page 65 and 66:
56Oral CommunicationsCO-070NORMAL F
Page 67 and 68:
58Oral CommunicationsCO-074VENOUS T
Page 69 and 70:
60Oral Communicationswith G20210A a
Page 71 and 72:
62Oral CommunicationsCO-081CLOTTING
Page 73 and 74:
64Oral Communications1. Decentraliz
Page 75 and 76: 66Oral Communicationsspontaneous re
Page 77 and 78: 68Oral Communicationsrecurrent DVT
Page 79 and 80: 70Oral Communicationsdata strenghte
Page 81 and 82: 72Oral Communicationscarrying the 5
Page 83 and 84: 74Oral Communicationsmorphism, but
Page 85 and 86: 76Oral CommunicationsCO-107HOMOCYST
Page 87 and 88: 78Oral Communicationsmost frequent
Page 89 and 90: 80Oral CommunicationsCO-115STUDY OF
Page 91 and 92: 82Oral Communicationsinformed conse
Page 93 and 94: 84Oral Communicationsnon-treated gr
Page 95 and 96: 86Oral CommunicationsTF expression
Page 97 and 98: 88Oral Communications@RISTOS, A PRO
Page 99 and 100: 90Oral CommunicationsOral Communica
Page 101 and 102: 92Oral CommunicationsCO-138EVALUATI
Page 103 and 104: 94PostersU/dL respectively. Convers
Page 105 and 106: 96Postersreport showing the presenc
Page 107 and 108: 98PostersPO-008INTEGRIN α2β1 AND
Page 109 and 110: 100Postersthe International Society
Page 111 and 112: 102PostersPO-017GASTROINTESTINAL BL
Page 113 and 114: 104PostersPO-021EVALUATION OF A NOV
Page 115 and 116: 106PostersVWF-LIA appears to be at
Page 117 and 118: 108PostersIn our hospital the routi
Page 119 and 120: 110PostersPO-032GENETIC RISK FACTOR
Page 121 and 122: 112PostersPO-036CATASTROPHIC VASCUL
Page 123 and 124: 114Postersprostanoide intravenously
Page 125: 116Posters5 mg folic acid daily, pl
Page 129 and 130: 120Postersexplanation of the increa
Page 131 and 132: 122Postersgonadal hormone replaceme
Page 133 and 134: 124Posters§Department of Nephrolog
Page 135 and 136: 126PostersPostersWOMEN'S HEALTH ISS
Page 137 and 138: 128Postersexcess of the anticoagula
Page 139 and 140: 130PostersC (APC- Resistance). The
Page 141 and 142: 132Postersgene substitution may be
Page 143 and 144: 134Postersof LMWH or OA for the tre
Page 145 and 146: 136Postersthe increased DVT risk as
Page 147 and 148: 138Postersinternal jugular vein thr
Page 149 and 150: 140PostersPostersANTIPLATELET THERA
Page 151 and 152: 142PostersPO-093MONITORING PLATELET
Page 153 and 154: 144PostersPostersACQUIRED COAGULATI
Page 155 and 156: 146Postersshowed significantly high
Page 157 and 158: 148PostersPO-105PROGNOSTIC SIGNIFIC
Page 159 and 160: 150Postersscreen and SCT confirm we
Page 161 and 162: 152PostersPO-114ECAPS STUDY: MULTIC
Page 163 and 164: 154Postersnary Intensive Therapy Un
Page 165 and 166: 156PostersPO-122GENOTYPE/PHENOTYPE
Page 167 and 168: 158PostersPO-126MATERNAL-FETAL THRO
Page 169 and 170: 160PostersPO-129RISK FACTOR FOR EXT
Page 171 and 172: 162Postersfirst VTE episode were en
Page 173 and 174: 164Postersative salvage and re-infu
Page 175 and 176: 166PostersPO-141CYTOMEGALOVIRUS INF
Page 177 and 178:
168PostersPO-145COMPLETE COMPRESSIO
Page 179 and 180:
170PostersBackground: Acutely ill m
Page 181 and 182:
172PostersPostersORAL ANTICOAGULANT
Page 183 and 184:
174PostersPO-156DIAGNOSTIC EFFICACY
Page 185 and 186:
176PostersPO-159ORAL ANTICOAGULATIO
Page 187 and 188:
178PostersPO-163BLEEDING RISK IN PA
Page 189 and 190:
180PostersHemorrhages represent the
Page 191 and 192:
182Postersma and native whole blood
Page 193 and 194:
184PostersPostersTHERAPY OF HEMOPHI
Page 195 and 196:
186PostersPO-179INHIBITOR DEVELOPEM
Page 197 and 198:
188PostersPO-183PROPOSAL OF IMMUNOT
Page 199 and 200:
190PostersAt the last follow-up, 11
Page 201 and 202:
192PostersPO-192SENSIBILITY OF THE
Page 203 and 204:
Campagna F 11Campagnoli MF 137Campa
Page 205 and 206:
Ieri M 142Iezzi A 11Ilari I 26, 167
Page 207 and 208:
Rotilio D 32, 33Rotoli B 145Rotunno
show all

Haematologica 2004;89: supplement no. 8 - Supplements ...

Create successful ePaper yourself

Delete template?

Save as template?